Latest publications

Allergen risk assessment: Food intake levels of the general population represent those of food allergic patients. Blom WM, Van Os-Medendorp H, Bijlsma S, Van Dijk A, Kruizinga AG, Rubingh C et al. Food Chem. Toxicol. 2020 Sep 25:111781

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry. Ariëns LF, Van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA et al. J. Am. Acad. Dermatol. 2020 Sep 15

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A et al. J Eur Acad Dermatol Venereol 2020 Sep 14

Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process. Thyssen JP, Heegaard S, Ivert L, Remitz A, Agner T, De Bruin-Weller M et al. Acta Derm. Venereol. 2020 Sep 16; 100(16):adv00264

Walnut Allergy across Europe: Distribution of Allergen Sensitization Patterns and Prediction of Severity. Lyons SA, Datema MR, Le TTM, Asero R, Barreales L, Belohlavkova S et al. J Allergy Clin Immunol Pract 2020 Sep 08

Detection of specific IgE against linear epitopes from Gal d 1 has additional value in diagnosing hen's egg allergy in adults. Ehlers AM, Otten HG, Wierzba E, Flügge U, Le TM, Knulst AC et al. Clin. Exp. Allergy 2020 Sep 10

Predicting food allergy: The value of patient history reinforced. Lyons SA, Knulst AC, Burney PGJ, Fernandez-Rivas M, Ballmer-Weber BK, Barreales L et al. Allergy 2020 Sep 07

Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. El Sharouni MA, Ahmed T, Witkamp AJ, Sigurdsson V, Van Gils CH, Nieweg OE et al. Br J Surg 2020 Aug 26

Can we define a level of protection for allergic consumers that everyone can accept? Madsen CB, Van den Dungen MW, Cochrane S, Houben GF, Knibb RC, Knulst AC et al. Regul. Toxicol. Pharmacol. 2020 Aug 05; 117:104751

Effective omalizumab interval prolongation in the treatment of chronic urticaria. Alizadeh Aghdam M, Pieterse RH, Kentie PA, Rijken F, Knulst AC, Röckmann H et al. J Allergy Clin Immunol Pract 2020 Jul 14

Systemic treatment in atopic dermatitis after 2018: from experienced-based treatment to evidence-based treatment? De Bruin-Weller M et al. Br. J. Dermatol. 2020 Jun 21

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, De Bruin-Weller M et al. Am J Clin Dermatol 2020 Aug; 21(4):567-577

Collodion babies: a 15-year retrospective multicenter study in the Netherlands. Evaluation of severity scores to predict the underlying disease. Cuperus E, Bolling MC, De Graaf M, Van den Akker PC, Van Gijn ME, Simon MEH et al. J. Am. Acad. Dermatol. 2020 Jun 11

Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers. Bakker DS, Nierkens S, Knol EF, Giovannone B, Delemarre EM, Van der Schaft J et al. J. Allergy Clin. Immunol. 2020 Jun 08

European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. Thyssen JP, Vestergaard C, Deleuran M, De Bruin-Weller MS, Bieber T, Taieb A et al. J Eur Acad Dermatol Venereol 2020 Jun 09:e16716